ERNA

Business Context and Reporting Period

Company: Eterna Therapeutics Inc. (Note: Request metadata listed "Ernexa Therapeutics Inc.", but the filing identifies the registrant as Eterna Therapeutics Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2025
Reporting Period: Specific event date of March 11, 2025.

Key Financial Metrics

This filing reports a specific financing transaction rather than periodic financial performance. Key metrics include:

• Debt Issued: $1,500,000 principal amount via Promissory Note.
• Interest Rate: 5.0% per annum (accrued, payable at maturity).
• Default Interest Rate: 7.0% per annum on overdue amounts.
• Liquidity Impact: Company received $1,500,000 in cash proceeds on March 11, 2025.
• Revenue/Profit/Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.

Material Changes

The primary material change is the entry into a Material Definitive Agreement (Item 1.01) and the creation of a Direct Financial Obligation (Item 2.03). The company has increased its indebtedness by $1.5 million to Charles Cherington. No prior comparable period financial data is provided in this document to assess year-over-year changes.

Guidance, Outlook, and Risks

Terms and Conditions:

• Maturity Date: The earliest of (a) June 15, 2025; (b) the first business day the Company raises over $5 million in equity or convertible debt proceeds post-issuance; or (c) an event of default.
• Payment Priority: Fees/charges, then accrued interest, then principal.
• Events of Default: Include failure to pay amounts due, breach of representations, failure to pay other indebtedness exceeding $50,000 after grace periods, and bankruptcy events.
• Acceleration: Upon an event of default, the holder may demand immediate repayment of all principal and accrued interest.

Outlook: The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the terms of the note.

Investor Verification Checklist

• Verify the identity of the lender, Charles Cherington, and any related party status.
• Confirm the company's current cash position and ability to repay the $1.5 million principal by June 15, 2025, or upon triggering the $5 million fundraising clause.
• Review the full text of the Promissory Note (Exhibit 10.1) for covenants not summarized in the 8-K.
• Monitor for any subsequent equity or debt issuances that would trigger early repayment of this note.